|

Epigenetic Profiling and Liquid Biopsy: Perspectives for Personalized Medicine in Meningioma Patients - MIND

RECRUITINGSponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Actively Recruiting
SponsorFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Started2024-09-25
Est. completion2026-03
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

Meningiomas are the most common primary intracranial tumors. Current treatment relies on surgical resection and radiotherapy, but molecular predictors for recurrence are lacking. This study aims to investigate epigenetic features, specifically histone post-translational modifications (PTMs) and DNA methylation, to stratify patients. The study involves a retrospective cohort to define an epigenetic signature and a prospective cohort to validate it in tissues and liquid biopsies (plasma/EVs).

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

Inclusion Criteria (Retrospective \& Prospective):

* Patient aged 18 years or older.
* First diagnosis of uni-focal meningioma of the convexity.
* Macroscopical total resection (Simpson 1-3).

(Retrospective only):

* Surgery performed between 2007 and 2016;
* availability of FFPE sample and medical records.

Exclusion Criteria:

* Genetic syndromes.
* Diffuse Meningeal Meningiomatosis.
* Patients who underwent experimental treatment in neo-adjuvant setting.

(Prospective only):

* Previous surgical/medical treatment for another meningioma;
* positive oncological history (e.g., breast cancer).

Conditions3

CancerMeningiomaMeningioma of Brain

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.